Transaction overview
A substantial insider-related disposition occurred at Ginkgo Bioworks Holdings Inc (NYSE:DNA) when 124,727 shares of Class A common stock were sold on April 10, 2026, at a per-share price of $6.434, yielding proceeds of approximately $802,493. The shares were indirectly held by Canton Barry through a spouse. The sale was executed explicitly to meet tax withholding obligations connected to a separate vesting event and was not a discretionary trade.
Vesting event and post-transaction holdings
One day prior, on April 9, 2026, 251,786 performance-based restricted stock units (PSUs) vested and were acquired. Following the subsequent sales to cover withholding, the remaining ownership attributable to the household stands at 436,422 shares. The report of these movements identifies the tax-driven nature of the disposition rather than an independent decision to reduce exposure.
Share performance and valuation context
Ginkgo's stock is trading at $6.68 and has fallen 51% over the last six months, a fall that InvestingPro highlights as indicative of notable volatility in DNA shares. The equity trades close to its 52-week low of $5.37. According to InvestingPro's Fair Value assessment cited in the transaction note, DNA appears undervalued relative to that model-derived benchmark.
Operational and financial developments
In its fourth-quarter 2025 results, the company reported progress on financial management and an operational restructuring program. While revenue in the cell engineering segment declined, management's aggressive cost-cutting work reduced operating losses and cash burn materially. Ginkgo also introduced the Ginkgo Cloud Lab - a cloud-based platform that lets researchers remotely access the firm’s automated laboratory infrastructure.
The Cloud Lab leverages Reconfigurable Automation Carts (RAC) that integrate robotic arms and maglev sample transport tracks to enable a modular lab configuration. The company is expanding its Autonomous Labs footprint and plans to double RAC cart automation in Boston by 2026, signaling continued investments in automation to improve throughput and potentially operating leverage.
Analyst reaction
Following the fourth-quarter call, BTIG reduced its price target for Ginkgo Bioworks from $9.00 to $5.00 and kept a Sell rating. The firm’s revised target and sell view were noted alongside the company’s efforts to streamline operations and roll out new lab automation offerings.
Concluding note
The insider-related sale was framed as a tax-driven transaction tied to PSU vesting, while the wider company narrative includes falling near-term revenue in a core segment, demonstrable reductions in operating losses and cash burn, and continued investment in automation products and lab platforms.